Showing results (151-160 of 290) with videos related to

Sort By:
Pageof 29
JCO Precision Oncology|August 7, 2018
Genomic Profiling of T-Cell Neoplasms Reveals Frequent <i>JAK1</i> and <i>JAK3</i> Mutations With Clonal Evasion From Targeted TherapiesAllison Greenplate, Kai Wang, Rati M Tripathi, et al.
The Oncologist|February 28, 2015
Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancerMarina Pekar-Zlotin, Fred R Hirsch, Lior Soussan-Gutman, et al.
Cancer Cytopathology|July 30, 2013
Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasmsGeneva Young, Kai Wang, Jie He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2019
On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating MutationBenjamin P Brown, Yun-Kai Zhang, David Westover, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2013
Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutationsJeffrey S Ross, Kai Wang, Christine E Sheehan, et al.
Pigment Cell & Melanoma Research|November 25, 2017
BRAF internal deletions and resistance to BRAF/MEK inhibitor therapyDouglas B Johnson, Merrida A Childress, Zachary R Chalmers, et al.
Oncoscience|August 6, 2015
Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplificationUmut Disel, Alexis Germain, Bahar Yilmazel, et al.
Lung Cancer (Amsterdam, Netherlands)|July 19, 2015
Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKISamuel J Klempner, Lyudmila A Bazhenova, Fadi S Braiteh, et al.
JCO Precision Oncology|September 9, 2020
Pan-Cancer Analysis of <i>BRCA1</i> and <i>BRCA2</i> Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of HeterozygosityEthan S Sokol, Dean Pavlick, Hossein Khiabanian, et al.
Cancer|December 10, 2015
Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterationsJeffrey S Ross, Kai Wang, Depinder Khaira, et al.
Pageof 29